Teacher Retirement System of Texas Buys 516,854 Shares of Ralliant Corporation $RAL

Teacher Retirement System of Texas lifted its stake in shares of Ralliant Corporation (NYSE:RAL) by 3,000.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 534,078 shares of the company’s stock after purchasing an additional 516,854 shares during the quarter. Teacher Retirement System of Texas’ holdings in Ralliant were worth $23,355,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in RAL. ST Germain D J Co. Inc. acquired a new position in Ralliant during the 2nd quarter worth approximately $27,000. Manchester Capital Management LLC bought a new stake in shares of Ralliant during the second quarter valued at approximately $29,000. Webster Bank N. A. acquired a new position in shares of Ralliant during the third quarter worth approximately $31,000. Evermay Wealth Management LLC bought a new position in shares of Ralliant in the 2nd quarter worth $32,000. Finally, Wilmington Savings Fund Society FSB acquired a new stake in Ralliant in the 3rd quarter valued at $34,000.

Ralliant Stock Down 1.1%

Ralliant stock opened at $53.70 on Friday. Ralliant Corporation has a 52 week low of $40.70 and a 52 week high of $55.25. The business’s 50 day moving average price is $50.76. The company has a market cap of $6.06 billion and a PE ratio of 42.28. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.03 and a current ratio of 1.49.

Ralliant (NYSE:RAL) last released its earnings results on Wednesday, November 5th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.02. The business had revenue of $529.10 million during the quarter, compared to the consensus estimate of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 23rd. Stockholders of record on Monday, December 8th were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, December 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Ralliant’s dividend payout ratio (DPR) is currently 15.75%.

Analyst Ratings Changes

RAL has been the topic of several research reports. Barclays upped their price objective on shares of Ralliant from $59.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, January 7th. Truist Financial began coverage on shares of Ralliant in a research report on Friday, December 12th. They set a “buy” rating and a $62.00 target price for the company. Citigroup raised shares of Ralliant from a “neutral” rating to a “buy” rating and raised their price target for the company from $53.00 to $61.00 in a research report on Monday, December 8th. Royal Bank Of Canada lifted their price target on Ralliant from $45.00 to $52.00 and gave the company a “sector perform” rating in a research note on Friday, November 7th. Finally, Oppenheimer boosted their price objective on Ralliant from $55.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $58.00.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.